Literature DB >> 28653739

Clinical significance of fascin-1 and laminin-5 in non-small cell lung cancer.

L Yang1, Y Teng2, T-P Han1, F-G Li1, W-T Yue2, Z-T Wang3.   

Abstract

Lung cancer is the leading cause of cancer death in men and the second leading cause of cancer death in women worldwide. Fascin-1 and laminin-5 were associated with the invasiveness and prognoses of several cancers. The expression and the serum levels of fascin-1 and laminin-5 in patients with non-small cell lung cancer (NSCLC) were analyzed in this study. The expression of fascin-1 and laminin-5 were examined in 378 patients and their serum level was measured in 154 patients. The health of all patients was followed post-surgery. The expression of fascin-1 (P = 0.000) and lanminin-5 (P = 0.001) and the serum levels of fascin-1 (P = 0.015) and laminin-5 (P = 0.046) were related to the relapse of patients with NSCLC. Both serum levels and expression of fascin-1 and laminin-5 can be used to effectively evaluate the prognoses of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28653739     DOI: 10.4238/gmr16029617

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study.

Authors:  Octavian Sabin Tătaru; Orsolya Martha; Felice Crocetto; Biagio Barone; Septimiu Voidazan; Angela Borda; Anca Sin; Adina Hutanu; Andrada Loghin; Ileana Sin; Daniel Porav-Hodade; Calin Bogdan Chibelean; Liliana Vartolomei; Giuseppe Lucarelli; Matteo Ferro; Virgil Gheorghe Osan; Carlo Buonerba; Mihai Dorin Vartolomei
Journal:  Future Sci OA       Date:  2021-06-30

Review 2.  The role of fascin-1 in the pathogenesis, diagnosis and management of respiratory related cancers.

Authors:  Naibin Zhang; Yankun Gao; Qiang Bian; Qianqian Wang; Ying Shi; Zhankui Zhao; Honglian Yu
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

3.  Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer.

Authors:  Giulia Cantini; Laura Fei; Letizia Canu; Giuseppina De Filpo; Tonino Ercolino; Gabriella Nesi; Massimo Mannelli; Michaela Luconi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-23       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.